Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. The company is headquartered in New York City, New York and currently employs 32 full-time employees. The company went IPO on 2019-05-09. The Company’s lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including classic galactosemia, sorbitol dehydrogenase (SORD) deficiency and phosphomannomutase 2 (PMM2)-congenital disorder glycosylation (CDG). The firm is also developing AT-001, an investigational, ARI developed as an oral therapy for the treatment of diabetic cardiomyopathy (DbCM). The company has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type II diabetes. The Company’s pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, and has demonstrated strong retinal penetrance, for the treatment of diabetic retinopathy (DR).
Follow-Up Questions
What is the price performance of APLT stock?
The current price of APLT is $0.4415, it has decreased 0.82% in the last trading day.
What are the primary business themes or industries for Applied Therapeutics Inc?
Applied Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Applied Therapeutics Inc market cap?
Applied Therapeutics Inc's current market cap is $63.5M
Is Applied Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for Applied Therapeutics Inc, including 4 strong buy, 3 buy, 4 hold, 0 sell, and 4 strong sell
